Will the FDA approve camizestrant for advanced breast cancer?
1.0 pts (24h)Health & MedicineOne-Off2m
KalshiVerificar disponibilidadeKYC obrigatório2% de taxaDados de resolução verificadosCalibração aproximadaProbabilidade implícita atualBefore Jan 1, 2028 77%Líder entre 5 opções
Qualidade do mercado
45 / 100
Baixa qualidadeVolume 24h
47 €
Liquidez
3,9 mil €
Liquidez médiaCompra / Venda
32.0% / 37.0%
Spread
5.0 pt
Spread moderadoDados do mercado
Atualizado há 24 minutos
14/05/26, 2:001/10/26, 3:59
Tendências
Apenas fundos simulados, sem dinheiro realIsto não é aconselhamento financeiro
Resultado escolhido
Before Oct 1, 202637%
Tendência de volume
$532 de jul.14d de dados28 de jul.
Mercados Relacionados
Will the FDA approve MDMA for PTSD?
0 €Before Jan 1, 2027: 10%KALSHI
KALSHI
Hantavirus pandemic in 2026?
106,1 mil €Sim: 3%
POLYMARKET
POLYMARKET
# of views of MrBeast video day 3?
6,5 mil €26-27M: 74%POLYMARKET
POLYMARKET
New pandemic in 2026?
5,2 mil €Sim: 9%POLYMARKET
POLYMARKET
Measles cases in 2026?
2,4 mil €Above 3000: 94%KALSHI
KALSHI
Pandemic in 2026?
2 mil €Sim: 6%KALSHI
KALSHIAtivos nestes tópicos
Regras
If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jun 1, 2026, then the market resolves to Yes.
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals: